A Modern Option for Hormonal Management in Companion Animals
As veterinary medicine shifts toward more personalised, evidence-based care, clients are increasingly asking about alternatives to permanent surgical castration. Suprelorin — a deslorelin implant — is one of the most clinically relevant tools available for managing testosterone-driven conditions in dogs, cats, and ferrets, without committing to an irreversible procedure.
Dr Melissa Court, Companion Animal Technical Services Veterinarian at Virbac Australia and a graduate of The University of Queensland with over 30 years of small animal experience, recently shared her clinical insights on where Suprelorin fits in modern practice and what realistic outcomes look like for veterinarians and their clients.
What Is Suprelorin?
Suprelorin is a subcutaneous deslorelin implant that temporarily suppresses reproductive hormone production by downregulating GnRH receptors in the pituitary gland. Unlike surgical castration, its effects are fully reversible — making it an important option for owners who want flexibility or need to avoid the risks of general anaesthesia.
Key clinical indications include:
- Healthy, intact male dogs seeking non-surgical fertility control
- High anaesthetic-risk patients
- Behavioural "trial" cases before permanent castration
- Benign prostatic hyperplasia (BPH)
- Temporary infertility in prepubertal female dogs
- Urine-marking control and fertility suppression in male cats
- Adrenal disease and fertility management in ferrets
Which Behavioural Problems Respond Best?
Owners frequently request hormonal management for behavioural concerns. According to Dr Court, testosterone-driven behaviours have the strongest response to Suprelorin, including:
- Roaming
- Urine marking
- Humping and hypersexual behaviour
- Inter-male aggression
- Libido-related behaviours in cats
However, not all behavioural issues are testosterone-dependent. Fear-based aggression, anxiety-driven behaviours, and aggression directed toward humans often show little improvement — and may even worsen in some patients following testosterone suppression. This distinction is critical when counselling owners, and hormonal management should ideally be paired with structured behavioural therapy.
Understanding the Testosterone Flare
One of the most important counselling points is the temporary hormone flare that follows implantation.
In the first 1–2 weeks after insertion, pituitary stimulation briefly increases testosterone levels before suppression takes effect. Owners may observe a short-term worsening of roaming, marking, libido, and aggression-related behaviours during this period.
It is equally important that owners understand:
- Dogs and cats remain fertile during the flare period
- Sperm production does not cease immediately
- Treated males should be separated from females in heat for approximately six weeks post-implantation
Monitoring testicular size reduction can provide reassurance to owners that suppression is taking effect.
How Quickly Does Suprelorin Work?
Behavioural Changes
- Male dogs: Behavioural improvement typically begins within 2–3 weeks once testosterone declines
- Male cats: Sexual behaviours may decrease within 1 week; significant reduction in libido and urine marking is generally seen by 4–6 weeks
Prostate Disease
For benign prostatic hyperplasia (BPH):
- Clinical improvement may begin within 1–2 weeks
- Significant prostate size reduction can occur within 6 weeks
- Some studies report up to 70% reduction in prostate volume over 9 weeks
Is Fertility Truly Reversible?
Yes — fertility recovery is one of Suprelorin's most valuable features.
- 4.7 mg implant: Testosterone recovery commonly occurs within 8–18 months
- 9.4 mg implant: Recovery may take 2–2.5 years
Viable sperm production typically resumes approximately 8–9 weeks after testosterone levels return to normal. For breeding dogs, Dr Court recommends confirming fertility status before implantation so that recovery can be meaningfully assessed.
Long-Term Safety
Current evidence indicates that repeated Suprelorin implants are generally well tolerated:
- No significant systemic adverse effects at recommended doses
- No major impacts on bone density
- No meaningful changes in renal or hepatic function
- Minimal injection-site reactions in the majority of patients
However, long-term data beyond four years of repeated use remains limited, and clinicians should exercise caution in:
- Cryptorchid dogs
- Mature female dogs for reproductive suppression
- Dogs with epilepsy
- Patients with known deslorelin hypersensitivity
Suprelorin as a Trial Before Surgery
One of the most compelling applications of Suprelorin in clinical practice is its role as a behavioural diagnostic tool before permanent castration.
If behaviours improve during the implant phase, surgical castration is likely to produce similar results. If behaviours do not improve, surgery is unlikely to resolve the primary concern.
> Studies cited in the interview suggest that behavioural outcomes predicted surgical results in approximately 81.7% of cases.
Notably, a significant proportion of owners who trialled Suprelorin ultimately chose not to proceed with surgical castration — often because the trial clarified that surgery would not address the root behavioural issue.
Suprelorin vs Surgical Castration: How to Frame the Conversation
| | Surgical Castration | Suprelorin |
|---|---|---|
| Duration | Permanent | Reversible |
| Anaesthesia | Required | Not required |
| Procedure | Operating theatre | Routine consultation |
| Recovery | Post-operative care needed | Minimal |
| Decision flexibility | None after surgery | Allows trialling first |
| Ongoing cost | One-time | Repeat implantation required |
Dr Court describes three practical ways to position Suprelorin to clients:
- A responsible first step before committing to irreversible surgery
- A way to reduce testosterone-driven conditions while maintaining the option for future breeding
- A lower-risk option for patients with anaesthetic concerns
Final Thoughts
Suprelorin is more than a surgical alternative — it is a diagnostic, behavioural, and medical management tool that can meaningfully improve the quality of care offered to companion animals and their owners.
When paired with realistic expectations and thorough owner counselling, it enables practices to deliver more personalised, evidence-based treatment pathways. For behavioural trial cases, anaesthetic-risk patients, or owners who simply aren't ready for a permanent decision, Suprelorin offers a clinically sound and increasingly well-supported middle ground.
---
Insights sourced from a clinical interview with Dr Melissa Court, Companion Animal Technical Services Veterinarian, Virbac Australia.
